Physician
Meghal V Parikh MD INC
Meghal V Parikh MD INC was paid $1.86M by Medicaid between Jan 2018 and Dec 2024, across 12 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 65% of everything it billed.
33Billing provider infoMEGHAL V PARIKH MD INC
MERCED, CA 95348
MERCED, CA 95348
33aNPI1447573472assigned 03/04/2010
33bProvider typeInternal Medicine Physician
28Total paid$1.86M
24GClaims17,785
24DCodes billed12
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in California
Rank by total paid#72 of 2,679
Median peer was paid$13K
This provider vs. median148×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,833 | $261K | |
| 2019 | 2,589 | $241K | |
| 2020 | 2,241 | $203K | |
| 2021 | 2,257 | $267K | |
| 2022 | 2,855 | $373K | |
| 2023 | 2,904 | $282K | |
| 2024incomplete | 2,106 | $238K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 65% | 13,454 | 13,257 | $1.22M |
| 99244 | Office or other outpatient consultation, moderate to high complexity | 20% | 2,041 | 2,040 | $369K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 3.9% | 69 | 66 | $73K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.3% | 897 | 889 | $61K |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | 2.6% | 41 | 38 | $49K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.5% | 383 | 354 | $47K |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 13 | 12 | $18K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 387 | 382 | $16K |
| 96415 | <1% | 347 | 323 | $10K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 90 | 90 | $2K |
| 20610 | <1% | 34 | 26 | $1K | |
| 76942 | <1% | 29 | 25 | $756.08 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPARIKH, MEGHAL (PRESIDENT)